BioMarin Pharmaceutical Inc (BMRN)
Industry Biotechnology
This stock can be held in an Investment ISA and an Investment Account
Sell
$55.32
Buy
$56.99
$-1.74 (-3.04%)
Prices updated at 02 Apr 2026, 23:18 EDT
| Prices minimum 15 mins delay
Prices in USD
Biomarin Pharmaceutical Inc is on rare-disease therapies. It develops and commercializes pharmaceuticals for serious diseases and medical conditions.
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Sector
Healthcare
Industry
Biotechnology
Chairman
Mr. Richard A. Meier
CEO
Mr. Alexander Hardy
Most recent earnings
31 Dec 2025
Fiscal year end
31 Dec 2025
Employees
3,221
Head office
770 Lindaro Street
San Rafael
United States
94901
Key personnel
Owner name | Salary |
|---|---|
Mr. Ian T. Clark Independent Director | - |
Mr. Richard A. Meier Chairman of the Board | 0.17m |
Mr. Timothy P. Walbert Independent Director | - |
Dr. Willard H. Dere, M.D. Independent Director | 0.10m |
Mr. Robert J. Hombach Independent Director | 0.10m |
Mr. Brian R. Mueller Executive Vice President, Finance and Chief Financial Officer | 0.70m |
Dr. Athena Countouriotis, M.D. Independent Director | 0.08m |
Mr. Mark Joseph Enyedy Independent Director | 0.10m |
Dr. Maykin Ho, PhD Independent Director | 0.10m |
Ms. Barbara W. Bodem Independent Director | 0.10m |
Ms. Elizabeth McKee Anderson, M.B.A. Independent Director | 0.10m |
Mr. Alexander Hardy Director, President and Chief Executive Officer | 1.05m |
Ms. Rashmi Virendra Ramchandani Vice President and Chief Accounting Officer | - |
Mr. G. Eric Davis Executive Vice President, Chief Legal Officer and Secretary | 0.72m |
Dr. Charles Greg Guyer, PhD Chief Technical Officer and Executive Vice President | - |
Ms. Cristin Hubbard Executive Vice President and Chief Commercial Officer | 0.38m |
Dr. Gregory R. Friberg, M.D. Executive Vice President and Chief Research and Development Officer | 0.16m |
Top 5 shareholders
Owner name | No. of shares |
|---|---|
| BlackRock Inc | 22,046,050 |
| Vanguard Group Inc | 18,127,847 |
| Dodge & Cox | 14,572,384 |
| PRIMECAP Management Company | 14,549,314 |
| BlackRock Fund Advisors | 11,319,081 |
Director dealings
Date | Action |
|---|---|
| 01 Dec 2025 | - |
| 30 Apr 2025 | - |
| 30 Sep 2025 | - |
| 01 Aug 2025 | - |
| 20 May 2025 | - |
| 20 May 2025 | - |
| 20 May 2025 | - |
| 20 May 2025 | - |
| 20 May 2025 | - |
| 20 May 2025 | - |
| 20 May 2025 | - |
| 20 May 2025 | - |
| 20 May 2025 | - |
| 20 May 2025 | - |
| 19 May 2025 | - |
| 20 May 2025 | - |
| 02 May 2025 | - |
| 30 Apr 2025 | - |
| 19 Mar 2025 | - |
| 17 Mar 2025 | - |
Please note that past performance is not a reliable indicator of future returns.
